Rationale: Drug-induced valvular heart disease (DI-VHD) remains an under-recognized entity.
Introduction
Benfluorex, a fenfluramine derivative, induces restrictive druginduced valvular heart disease (DI-VHD) [1] and seldom pulmonary arterial hypertension. [2] In most cases, the severity of DI-VHD is mild but may be severe and requires valve surgery [1] The case describes a benfluorex-exposed patient who underwent mitral and aortic valve replacement but died postoperatively because of systemic pulmonary hypertension. Valve pathology analysis demonstrated anorexigen-induced fibrosis. [3] Informed consent was obtained from the mother of the patient.
Case presentation
A 61-year-old female patient was referred for mitral and aortic valve replacement. She had a history of obesity, hypothyroidism, hypertension, smoking, type 2-diabetes, and 6.5-years-benfluorex intake that was interrupted 2 years ago. She reported a 4 year history of increasingly severe episodes of acute respiratory distress initially accounted to exacerbation of chronic obstructive pulmonary disease. Doppler echocardiography examination found normal left ventricular end-diastolic diameter (45 mm) with normal ejection fraction (75%), enlarged left atrium, moderate aortic regurgitation with thickened leaflets, and mild restrictive mitral regurgitation with thickened, and shortened leaflet and subvalvular apparatus resulting in significant mitral stenosis (mean gradient 15 mm Hg, valve area below 1.3 cm 2 ). Right heart catheterization showed mean pulmonary capillary wedge pressure at 39 mm Hg, heightened pulmonary pressures (systolic 82-diastolic 38/mean 56 mm Hg) and right atrial pressure (21 mm Hg). Lung function tests showed forced expiratory volume-1 at 74%, Tiffeneau-index 70%, PO 2 83 mm Hg, and PCO 2 at 32 mm Hg. No sleep disorder was found. The patient underwent mitral and aortic valve replacement with mechanical bileaflet valves. Peroperative findings were severely enlarged pulmonary trunk, noncalcified funnel-shaped mitral apparatus associated with leaflet thickening and commissural fusion (Fig. 1, panels A, B ). Due to extreme chordal tendinae retraction, mitral leaflets were fused with papillary muscles. In contrast aortic leaflets were thin with noncoronary cusp prolapse (Fig. 1, panel C) . Intraoperative transesophageal echocardiography showed normal valve prostheses and right and left ventricle function. However, systemic pulmonary hypertension (mean pulmonary artery pressure 53 mm Hg, mean systemic arterial pressure 58 mm Hg) developed and the patient died despite administration of inotropic agents and nitric oxide as well as prolonged extracorporeal life support. Pathology examination demonstrated drug-induced valvular disease by demonstrating noninflammatory endocardial fibrosis on both mitral (Fig. 1 , panels D, E) and aortic valves (Fig. 1, panels F, G) .
Discussion
Since World War II, the incidence of rheumatic fever as a main cause of restrictive valvular disease has declined significantly and has been progressively replaced in Western countries by other etiologies including degenerative, genetic, radiation-induced, or drug-induced valve disease.
Activation of the 5-HT2B receptor by norfenfluramine (the active metabolite of benfluorex as well as fenfluramine and dexfenfluramine) is thought to be the main mechanism of development of DI-VHD. [3] 5-HT2B receptors activation produces valvular endocardial fibrosis with thickened and retracted leaflets associated with chordae tendinae thickening, fusion, and retraction of the subvalvular mitral apparatus. Pathology analysis shows that the valve architecture is well preserved without inflammation or neovascularization. [3] In contrast rheumatic heart disease leads to scarring fibrosis, inflammatory damage with disruption of the valve layers and with neoangiogenesis including thick-wall vessels. Finally anorexigen exposure produces distinctive valvular lesions from other valvular disease etiologies. [4] Calcifications may noteworthy be observed in both etiologies. [5] In clinical practice DI-VHD often produces severe symptoms despite mild or moderate regurgitation due to restrictive valve opening and thereby pulmonary hypertension. The restrictive mitral valve disease may be dynamic with exercise or loading conditions; [6] repeated mitral regurgitation worsening directly impacts on left atrial pressure and thereby pulmonary artery pressures. Of note commissural fusions thought to be specific to rheumatic fever may also be found in benfluorex-induced VHD and further aggravate leaflet opening restriction and symptoms. [7] Dexfenfluramine-related endocardial cardiac fibrosis producing restrictive physiology remains to be demonstrated in benfluorex treated patients. [8] Although preoperative cardiac catheterization showed postcapillary pulmonary hypertension, the patient immediately developed systemic pulmonary hypertension following valve replacement similar to pulmonary arterial hypertension suggesting an additional precapillary component. Interestingly in the present case, in addition to aortic valve cusp prolapse which is common finding in benfluorex-induced VHD, [9] the cusps were found to be intraoperatively normal despite pathological features of DI-VHD.
In conclusion, a history of heart failure or valve replacement related to restrictive valvular disease in a patient without history of rheumatic fever should alert the clinician of potential adverse drug effect.
